SNU-1040 人結(jié)腸癌細(xì)胞
Catalogue No.: C1119
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%IMDM+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

rates of 16-22 % with overall survival rates of 6-8 months in seriously ill patients with HNSCC who already had a first- and/or even second-line therapy. Nivolumab and Pembrolizumab are currently approved in Germany for the first and second line therapy of relapsed/pktastatic